HK1222564A1 - 靶向癌症、尤其是前列腺癌的合成性抗體模擬化合物 - Google Patents

靶向癌症、尤其是前列腺癌的合成性抗體模擬化合物

Info

Publication number
HK1222564A1
HK1222564A1 HK16110785.0A HK16110785A HK1222564A1 HK 1222564 A1 HK1222564 A1 HK 1222564A1 HK 16110785 A HK16110785 A HK 16110785A HK 1222564 A1 HK1222564 A1 HK 1222564A1
Authority
HK
Hong Kong
Prior art keywords
syams
cancer
synthetic antibody
antibody mimetic
mimetic compounds
Prior art date
Application number
HK16110785.0A
Other languages
English (en)
Inventor
David A Spiegel
Patrick Mcenaney
Kelly Fitzgerald
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of HK1222564A1 publication Critical patent/HK1222564A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK16110785.0A 2013-05-03 2016-09-12 靶向癌症、尤其是前列腺癌的合成性抗體模擬化合物 HK1222564A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/039472 WO2014178878A1 (en) 2013-05-03 2013-05-03 Synthetic antibody mimetic compounds (syams) targeting cancer, especially prostate cancer

Publications (1)

Publication Number Publication Date
HK1222564A1 true HK1222564A1 (zh) 2017-07-07

Family

ID=51843839

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16110785.0A HK1222564A1 (zh) 2013-05-03 2016-09-12 靶向癌症、尤其是前列腺癌的合成性抗體模擬化合物

Country Status (7)

Country Link
US (3) US10117943B2 (zh)
EP (1) EP2991677B1 (zh)
JP (1) JP6473138B2 (zh)
CN (1) CN105407920B (zh)
ES (1) ES2824026T3 (zh)
HK (1) HK1222564A1 (zh)
WO (1) WO2014178878A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013070688A1 (en) 2011-11-11 2013-05-16 Yale University Reprogramming urokinase into an antibody-recruiting anticancer agent
WO2013166110A1 (en) 2012-05-02 2013-11-07 Yale University Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
WO2017023994A1 (en) 2015-08-06 2017-02-09 Yale University Small molecule based antibody-recruiting compounds for cancer treatment
US10780084B2 (en) 2016-08-03 2020-09-22 Yale University Antibody-recruiting molecules for the treatment of cancer
CN111148527A (zh) * 2017-07-26 2020-05-12 克莱奥药品有限公司 通用abt化合物及其用途
EP3773727A4 (en) * 2018-04-09 2022-05-04 Yale University BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS
US11767301B2 (en) 2018-04-09 2023-09-26 Yale University Bi-functional molecules to degrade circulating proteins
US20230083388A1 (en) * 2018-04-09 2023-03-16 Yale University Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins
US11065336B2 (en) * 2018-04-30 2021-07-20 Medimmune Limited Conjugates for targeting and clearing aggregates
GB201816554D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
US20220023434A1 (en) 2018-12-19 2022-01-27 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods
US20220175819A1 (en) * 2019-04-19 2022-06-09 Fount Bio, Inc. Delivery and retention of active agents within the skin
JP2022551867A (ja) * 2019-10-10 2022-12-14 イエール ユニバーシティ 細胞受容体を通じた分子分解剤としての操作された抗体
CN113354712B (zh) * 2021-06-11 2023-10-13 江苏省原子医学研究所 一种酶靶向控制分子内缩合分子探针及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
MXPA02000961A (es) * 1999-07-29 2003-08-20 Medarex Inc Anticuerpos monoclonales humanos para antigeno de membrana especifico de la prostata.
DE60036388D1 (de) * 1999-07-30 2007-10-25 Medarex Inc Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen
US7235641B2 (en) * 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
WO2009090268A1 (en) * 2008-01-17 2009-07-23 Medimmune Limited Peptide mimetics
PL2291659T3 (pl) * 2008-05-13 2016-04-29 Univ Yale Małe cząsteczki chimerowe do rekrutacji przeciwciał do komórek nowotworowych
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
HRP20221195T1 (hr) 2009-03-19 2022-12-09 The Johns Hopkins University Spojevi koji ciljaju psma i njihova uporaba
US9181224B2 (en) * 2009-10-13 2015-11-10 Yale University Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
WO2012068366A2 (en) 2010-11-18 2012-05-24 Yale University Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus

Also Published As

Publication number Publication date
US10912836B2 (en) 2021-02-09
US20190209696A1 (en) 2019-07-11
US10117943B2 (en) 2018-11-06
CN105407920B (zh) 2019-12-13
JP2016529204A (ja) 2016-09-23
EP2991677A1 (en) 2016-03-09
EP2991677B1 (en) 2020-07-15
US20160082112A1 (en) 2016-03-24
JP6473138B2 (ja) 2019-02-20
CN105407920A (zh) 2016-03-16
ES2824026T3 (es) 2021-05-11
WO2014178878A1 (en) 2014-11-06
US20220111060A1 (en) 2022-04-14
EP2991677A4 (en) 2016-12-14

Similar Documents

Publication Publication Date Title
HK1222564A1 (zh) 靶向癌症、尤其是前列腺癌的合成性抗體模擬化合物
IL292193A (en) Anti-b7–h1 antibodies for the treatment of tumors
HK1217218A1 (zh) 結直腸癌生物標誌物
HK1223552A1 (zh) 用於癌症的組合療法
EP3083682C0 (en) DOUBLE SPECIFICITY ANTIBODIES
HK1218552A1 (zh) 有特異性的抗體結合位點
IL246067A0 (en) Classification of prostate cancer
EP3046561A4 (en) Compounds for treating prostate cancer
EP3008092A4 (en) Targeting tumor neovasculature with modified chimeric antigen receptors
EP3083698A4 (en) Monoclonal anti-tk1 antibodies
PL2984871T3 (pl) Operacja pdcp w celu podwójnego połączenia
EP3008210A4 (en) Methods for detecting prostate cancer
EP3085380A4 (en) Composition for treating prostate cancer
GB201322800D0 (en) Prostate cancer biomarkers
EP3044335A4 (en) Predicting breast cancer recurrence
HK1224010A1 (zh) 卵巢癌生物標誌物
HK1216779A1 (zh) 用於癌症治療的預測性生物標記物
HK1220356A1 (zh) 用於前列腺癌的新穎療法
HK1217340A1 (zh) 針對 的單克隆抗體
EP3015476A4 (en) Tumor biomarker
GB201319374D0 (en) Glycans as functional cancer targets abd antibodies thereto
HK1215714A1 (zh) -- -甲基苯丙胺單克隆抗體
EP3033617A4 (en) Biomarkers for prostate cancer
ZA201504169B (en) Anti-adam28 antibody for treating cancer
HK1211301A1 (zh) 抗體